Keyur P. Patel
YOU?
Author Swipe
View article: Mutational Landscape and Clinical Impact of SPEN Mutations in Patients with Chronic Lymphocytic Leukemia
Mutational Landscape and Clinical Impact of SPEN Mutations in Patients with Chronic Lymphocytic Leukemia Open
Background/Objectives: NOTCH1 is frequently mutated in chronic lymphocytic leukemia (CLL) and is a marker of poor prognosis. In addition to NOTCH1, mutations in the NOTCH1 regulatory pathway including SPEN have been described in a limited …
View article: Clonal dynamics of FLT3-ITD positive acute myeloid leukemia following relapse after allogeneic stem cell transplantation
Clonal dynamics of FLT3-ITD positive acute myeloid leukemia following relapse after allogeneic stem cell transplantation Open
Introduction: Allogeneic stem cell transplantation (alloSCT) offers a potential cure for patients with FLT3-internal tandem duplication (ITD)-mutated acute myeloid leukemia (AML), particularly when performed in first complete remission (CR…
View article: Comparative Analysis of Targeted RNA-Seq and Optical Genome Mapping for Detecting Gene Rearrangements in Acute Leukemia
Comparative Analysis of Targeted RNA-Seq and Optical Genome Mapping for Detecting Gene Rearrangements in Acute Leukemia Open
Background/Objectives: Gene rearrangements involving oncogenes are major drivers in acute leukemia, influencing disease classification, prognosis, and therapeutic decision-making. Targeted RNA sequencing (RNA-Seq) panels capable of detecti…
View article: Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression Open
View article: Supplementary Figure 2 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Figure 2 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Figure 2. Summary of genomic landscape in patients enrolled based on outside laboratory testing who had discordant mutations. Patients are stratified according to the site of tissue biopsy (primary or metastatic site). Triang…
View article: Supplementary Figure 7 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Figure 7 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Figure 7. Genetic alterations detected in patients treated in subprotocol W enrolling patients with FGFR pathway alterations who received treatment with AZD4547. Patients are stratified according to the best overall response.…
View article: Supplementary Table 3 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Table 3 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Table 3. List of tissue alterations of interest not covered by the used liquid biopsy assay (duplicate values were removed from the table).
View article: Supplementary Table 4 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Table 4 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Table 4. Gene list used to determine actionability.
View article: Prognostic and Therapeutic Implications of <i>BRAF</i> Mutations in Acute Myeloid Leukemia
Prognostic and Therapeutic Implications of <i>BRAF</i> Mutations in Acute Myeloid Leukemia Open
Mutations in the RAS/MAPK signaling pathway are recurrent in acute myeloid leukemia (AML), primarily involving NRAS and KRAS . In contrast, mutations in the gene encoding an effector protein, BRAF, occur at relatively lower frequencies in …
View article: Supplementary Table 8 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Table 8 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Table 8. Concordance of alteration of interest according to detailed histology in patients enrolled based on outside designated laboratory testing (n = 57).
View article: Supplementary Table 7 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Table 7 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Table 7. Concordance of alteration of interest according to type of alteration, treatment arm, and diagnostic group in patients enrolled based on outside designated laboratory testing (n = 57).
View article: Supplementary Table 2 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Table 2 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Table 2. Overlapping genes between Guardant360 and Oncomine.
View article: Data from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Data from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Purpose:Liquid biopsies with circulating tumor DNA (ctDNA) analysis are increasingly being utilized as a noninvasive approach to identify actionable genomic alterations in advanced/metastatic cancers. In this study, we report the correlati…
View article: Supplementary Table 1 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Table 1 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Table 1. Prioritized subprotocols of NCI-MATCH that were included in plasma analysis.
View article: Supplementary Table 9 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Table 9 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Table 9. Distribution of different genetic alterations according to response groups in different treatment arms. Shown in the table is the number of patients with molecular alteration in each response category.
View article: Supplementary Figure 6 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Figure 6 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Figure 6. Genomic alterations detected in patients treated in subprotocol S1 enrolling patients with NF1 mutations who received treatment with trametinib. Patients are stratified according to the best overall response. Triang…
View article: Supplementary Figure 8 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Figure 8 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Figure 8. Genomic alterations detected in patients treated in subprotocol Z1A enrolling patients with NRAS mutations who received treatment with binimetinib. Patients are stratified according to the best overall response. Tri…
View article: Supplementary Figure 9 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Figure 9 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Figure 9. Difference in baseline maximum VAF for detected somatic alterations. Panel (a) shows the maximum VAF according to the response category in patients with evaluable disease in the overall cohort. Panel (b) shows furth…
View article: Supplementary Figure 3 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Figure 3 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Figure 3. Genomic alterations detected in patients treated in subprotocol G enrolling patients with ROS1 translocations who received treatment with crizotinib. Patients are stratified according to the best overall response. T…
View article: Supplementary Table 10 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Table 10 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Table 10. Correlations between concordance rates (detection of tissue alterations of interest in plasma) and response category in patients with evaluable disease who were enrolled based on central testing.
View article: Supplementary Results 1 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Results 1 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Results 1. Detailed results about actionability.
View article: Supplementary Figure 5 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Figure 5 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Figure 5. Genomic alterations detected in patients treated in subprotocol Q enrolling patients with HER2 amplifications who received treatment with ado-trastuzumab emtansine. Patients are stratified according to the best over…
View article: Supplementary Table 5 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Table 5 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Table 5. List of alterations of interest that were discordant between tissue and plasma in patients enrolled based on central testing.
View article: Supplementary Table 6 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Table 6 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Table 6. Concordance of alteration of interest according to detailed histology in patients enrolled based on central testing (n = 243).
View article: Supplementary Figure 4 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Figure 4 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Figure 4. Genomic alterations detected in patients treated in subprotocol I enrolling patients with PIK3CA mutations who received treatment with taselisib. Patients are stratified according to the best overall response. Trian…
View article: Supplementary Figure 1 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Supplementary Figure 1 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131) Open
Supplementary Figure 1. Cell-free DNA yield in included patients. Yield is presented in ng per ml plasma and categorized according to the diagnostic group.
View article: Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor Open
Triplet regimens with a hypomethylating agent, venetoclax and a FLT3 inhibitor yield high rates of response in newly diagnosed FLT3-mutated AML. However, the long-term outcomes and patterns of relapse with these triplet regimens are not we…
View article: Cutaneous Metastasis of Gastric Adenocarcinoma: A Report of a Rare Case and a Literature Review
Cutaneous Metastasis of Gastric Adenocarcinoma: A Report of a Rare Case and a Literature Review Open
View article: Glucagon-Like Peptide-1 Receptor Agonists Taken for Weight Loss Do Not Affect Postoperative Outcomes Following Anterior Cervical Discectomy And Fusion
Glucagon-Like Peptide-1 Receptor Agonists Taken for Weight Loss Do Not Affect Postoperative Outcomes Following Anterior Cervical Discectomy And Fusion Open
Study Design: Retrospective cohort study. Objective: To investigate surgical and patient-reported outcome measures (PROM) after anterior cervical discectomy and fusion (ACDF) for patients taking glucagon-like peptide-1 (GLP-1) receptor ago…
View article: 272 | ACALABRUTINIB IN COMBINATION WITH RITUXIMAB IS HIGHLY EFFECTIVE FRONTLINE TREATMENT FOR OLDER PATIENTS WITH MANTLE CELL LYMPHOMA
272 | ACALABRUTINIB IN COMBINATION WITH RITUXIMAB IS HIGHLY EFFECTIVE FRONTLINE TREATMENT FOR OLDER PATIENTS WITH MANTLE CELL LYMPHOMA Open